AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24337619 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 0
Study 20597808 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week progressive resistance exercise training programme
Number of subjects: 20
Study 20597808 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (Control)
Number of subjects: 20
Study 19954587 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 120
Study 19954587 — intervention group
Group type: COMPARATOR
Intervention: Conventional White Light
Number of subjects: 120
Study 18021143 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm packs applied to the perineum (n = 360)
Number of subjects: 717
Study 18021143 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 357)
Number of subjects: 717
Study 15356044 — intervention group
Group type: EXPERIMENTAL
Intervention: PTU pretreatment (n = 39)
Number of subjects: 80
Study 15356044 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (n = 41)
Number of subjects: 80
Study 11682422 — intervention group
Group type: EXPERIMENTAL
Intervention: IQB‐9302 (0.25%)
Number of subjects: 12
Study 11682422 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (0.25%)
Number of subjects: 12
Study 11682422 — intervention group
Group type: EXPERIMENTAL
Intervention: IQB‐9302 (0.5%)
Number of subjects: 12
Study 11682422 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (0.5%)
Number of subjects: 12
Study 9649059 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of LMW heparin (nadroparin) 12,500 ICU AXa at the beginning of dialysis
Number of subjects: 9
Study 9649059 — intervention group
Group type: COMPARATOR
Intervention: Priming dose of nadroparin 10,000 ICU AXa at the beginning of dialysis followed by a supplementary dose of nadroparin 2,500 ICU AXa at the beginning of the fifth hour of dialysis
Number of subjects: 9
Study 7521582 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin in standard doses
Number of subjects: 100
Study 7521582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2672492 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazemuls (10 mg)
Number of subjects: 224
Study 2672492 — intervention group
Group type: COMPARATOR
Intervention: Valium Mixed Micelles (10 mg)
Number of subjects: 224
Study 338983 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin plus Dapsone
Number of subjects: 0
Study 338983 — intervention group
Group type: COMPARATOR
Intervention: Dapsone (DDS)
Number of subjects: 0
Study 31909868 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 494
Study 31415411 — intervention group
Group type: EXPERIMENTAL
Intervention: Health management group (155 cases)
Number of subjects: 300
Study 31415411 — intervention group
Group type: COMPARATOR
Intervention: Control group (145 cases)
Number of subjects: 300
Study 29376240 — intervention group
Group type: EXPERIMENTAL
Intervention: Dingkun Dan
Number of subjects: 75
Study 29376240 — intervention group
Group type: COMPARATOR
Intervention: Fuke Zaizao Jiaonang (Control)
Number of subjects: 75
Study 25633506 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniperc
Number of subjects: 212
Study 25633506 — intervention group
Group type: COMPARATOR
Intervention: Shockwave Lithotripsy (SWL)
Number of subjects: 212
Study 23891702 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) 0.5μg/(kg body weight) intravenously administered for 24h
Number of subjects: 16
Study 23891702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21716251 — intervention group
Group type: EXPERIMENTAL
Intervention: Neyromidin (ipidacrinum) used in intramuscular injections
Number of subjects: 58
Study 21716251 — intervention group
Group type: EXPERIMENTAL
Intervention: Neyromidin (ipidacrinum) introduced by local injection perineural therapy
Number of subjects: 58
Study 19701041 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical success defined as absence of prolapse beyond the hymen
Number of subjects: 0
Study 19701041 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective cure (absence of bulge symptoms)
Number of subjects: 0
Study 19701041 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of re‐treatment
Number of subjects: 0
Study 19701041 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall improvement and treatment success rating
Number of subjects: 0
Study 19701041 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitions of success requiring all anatomic support to be proximal to the hymen
Number of subjects: 0
Study 19701041 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective cure
Number of subjects: 0
Study 19701041 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom burden and health-related quality of life
Number of subjects: 0
Study 16731464 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Atrial Triad
Number of subjects: 36
Study 16731464 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Atrial Triad
Number of subjects: 36
Study 16731464 — intervention group
Group type: COMPARATOR
Intervention: Ventricular Triad
Number of subjects: 36
Study 14647880 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 150 micro g
Number of subjects: 386
Study 14647880 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 300 micro g
Number of subjects: 386
Study 14647880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 11721100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (body-weight adjusted intravenous) for a mean period of 46 hours
Number of subjects: 35
Study 11721100 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched group of 17 acute ischemic clinically stable stroke patients)
Number of subjects: 35
Study 11721100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 35
Study 9408710 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8334344 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 24
Study 8334344 — intervention group
Group type: COMPARATOR
Intervention: Verapamil plus Renal Disease Basic-prescription (RDBP)
Number of subjects: 24
Study 3557792 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin alone
Number of subjects: 39
Study 3557792 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin in combination with isoniazid
Number of subjects: 39
Study 28470563 — intervention group
Group type: EXPERIMENTAL
Intervention: Qishen Yiqi Dripping Pills (QSYQ)
Number of subjects: 80
Study 28470563 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular medication only)
Number of subjects: 80
Study 26114234 — intervention group
Group type: EXPERIMENTAL
Intervention: Group medical consultations (GMCs)
Number of subjects: 122
Study 26114234 — intervention group
Group type: COMPARATOR
Intervention: Individual medical visits (control)
Number of subjects: 122
Study 25219130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping + acupuncture
Number of subjects: 60
Study 25219130 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture + TDP
Number of subjects: 60
Study 22626580 — intervention group
Group type: EXPERIMENTAL
Intervention: elocalcitol 75 μg/d
Number of subjects: 308
Study 22626580 — intervention group
Group type: EXPERIMENTAL
Intervention: elocalcitol 150 μg/d
Number of subjects: 308
Study 22626580 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 308
Study 20838991 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily
Number of subjects: 19
Study 20838991 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for PMs
Number of subjects: 19
Study 18389444 — intervention group
Group type: EXPERIMENTAL
Intervention: PillCam ESO 2
Number of subjects: 28
Study 18389444 — intervention group
Group type: COMPARATOR
Intervention: EGD
Number of subjects: 28
Study 17119719 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracapsular cataract extraction (ECCE)
Number of subjects: 41
Study 17119719 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 41
Study 12932668 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant alternating chemotherapy and radiation at the coordinating centre
Number of subjects: 293
Study 12932668 — intervention group
Group type: COMPARATOR
Intervention: Concomitant alternating chemotherapy and radiation at the affiliated centres
Number of subjects: 293
Study 12932668 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone at the coordinating centre
Number of subjects: 293
Study 12932668 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone at the affiliated centres
Number of subjects: 293
Study 11916762 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (60 mg Fe/d, 4 d/wk for 16 wk)
Number of subjects: 166
Study 11916762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 9699402 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary expansion and protraction facemask
Number of subjects: 20
Study 8017306 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial neural networks for diagnosing anterior myocardial infarction
Number of subjects: 1107
Study 8017306 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrocardiographic criteria for diagnosing anterior myocardial infarction
Number of subjects: 1107
Study 8017306 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial neural networks for diagnosing inferior myocardial infarction
Number of subjects: 1107
Study 8017306 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrocardiographic criteria for diagnosing inferior myocardial infarction
Number of subjects: 1107
Study 3137218 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (primary depressives N = 13, secondary depressives N = 6)
Number of subjects: 37
Study 3137218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (primary depressives N = 12, secondary depressives N = 6)
Number of subjects: 37
Study 31068215 — intervention group
Group type: EXPERIMENTAL
Intervention: Target temperature management at 33 °C
Number of subjects: 853
Study 31068215 — intervention group
Group type: COMPARATOR
Intervention: Target temperature management at 36 °C
Number of subjects: 853
Study 28143463 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensors monitoring training activity during gait-related balance exercise
Number of subjects: 10
Study 25593015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 400mg/m² IV on day 1 followed by 250mg/m² IV weekly (Arm A)
Number of subjects: 55
Study 25593015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 400mg/m² IV on day 1 followed by 250mg/m² IV weekly plus sorafenib 400mg PO twice-a-day (Arm B)
Number of subjects: 55
Study 25593015 — intervention group
Group type: COMPARATOR
Intervention: p16-negative tumors
Number of subjects: 55
Study 25593015 — intervention group
Group type: COMPARATOR
Intervention: Higher TGFβ1 levels
Number of subjects: 55
Study 23826087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional meglumine antimoniate (i.l.MA)
Number of subjects: 83
Study 23826087 — intervention group
Group type: COMPARATOR
Intervention: Intralesional meglumine antimoniate (i.l.MA) + non-silver dressing
Number of subjects: 83
Study 23826087 — intervention group
Group type: COMPARATOR
Intervention: Intralesional meglumine antimoniate (i.l.MA) + silver dressing
Number of subjects: 83
Study 21685644 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive VR distraction
Number of subjects: 68
Study 21685644 — intervention group
Group type: COMPARATOR
Intervention: Passive VR distraction
Number of subjects: 68
Study 19233678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioblate group (mitral valve surgery plus biatrial modified radiofrequency Maze procedure)
Number of subjects: 49
Study 19233678 — intervention group
Group type: COMPARATOR
Intervention: Control group (mitral valve surgery plus intensive rhythm control strategy)
Number of subjects: 49
Study 19233678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioblate group
Number of subjects: 49
Study 19233678 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 16404038 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia educational interface 1
Number of subjects: 0
Study 16404038 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia educational interface 2
Number of subjects: 0
Study 16404038 — intervention group
Group type: COMPARATOR
Intervention: Traditional approach
Number of subjects: 0
Study 15596636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system, 30 mg/d
Number of subjects: 0
Study 15596636 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide-amiloride (25 mg/d of hydrochlorothiazide and 2.5 mg/d of amiloride hydrochloride)
Number of subjects: 0
Study 15596636 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum creatinine levels
Number of subjects: 0
Study 15596636 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal serum creatinine levels
Number of subjects: 0
Study 15596636 — intervention group
Group type: EXPERIMENTAL
Intervention: Low creatinine clearance (<60 mL/min)
Number of subjects: 0
Study 11387278 — intervention group
Group type: EXPERIMENTAL
Intervention: Semen collection into 20 ml HEPES buffered Ham's F‐10 medium with 10% human serum albumin (group B)
Number of subjects: 114
Study 11387278 — intervention group
Group type: COMPARATOR
Intervention: Semen collection into sterile dry pots (group A)
Number of subjects: 114
Study 9403642 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (200 U/kg/day)
Number of subjects: 28
Study 9403642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9403642 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO
Number of subjects: 28
Study 8427643 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine merino sheepskin (WoolTec USA, Maspeth, NY)
Number of subjects: 108
Study 8427643 — intervention group
Group type: COMPARATOR
Intervention: Synthetic sheepskin
Number of subjects: 108
Study 3595971 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 1 mg of ONO-802 vaginal suppository every 3 hours (maximum of five suppositories)
Number of subjects: 48
Study 3595971 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 1 mg of ONO-802 vaginal suppository (maximum of three suppositories)
Number of subjects: 48
Study 30993934 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic rabbits with contrast agent (DCA)
Number of subjects: 62
Study 30993934 — intervention group
Group type: COMPARATOR
Intervention: Healthy rabbits with contrast agent (NCA)
Number of subjects: 62
Study 28422346 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-arm elevation above shoulder level
Number of subjects: 10
Study 28422346 — intervention group
Group type: COMPARATOR
Intervention: Single-arm elevation
Number of subjects: 10
Study 28422346 — intervention group
Group type: COMPARATOR
Intervention: Double-arm elevation below shoulder level
Number of subjects: 10
Study 28422346 — intervention group
Group type: COMPARATOR
Intervention: Single-limb leg extensions
Number of subjects: 10
Study 26073498 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood induction (positive imagery training; PIT)
Number of subjects: 0
Study 26073498 — intervention group
Group type: COMPARATOR
Intervention: Control (positive verbal training; PVT)
Number of subjects: 0
Study 23320469 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.3% mouth rinse for 15 seconds
Number of subjects: 20
Study 23320469 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine 0.2% mouth rinse for 30 seconds
Number of subjects: 20
Study 21598886 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary open reduction internal fixation (ORIF) by bioabsorbable screws via a Smith‐Petersen approach
Number of subjects: 24
Study 21598886 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction (conservative treatment)
Number of subjects: 24
Study 19917956 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriol
Number of subjects: 30
Study 19917956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16510122 — intervention group
Group type: EXPERIMENTAL
Intervention: XRCC1 399Gln variant
Number of subjects: 292
Study 16510122 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐A haplotype of XRCC1 194 Trp and XRCC1 399Gln
Number of subjects: 292
Study 16510122 — intervention group
Group type: COMPARATOR
Intervention: Other polymorphic loci
Number of subjects: 292
Study 15570082 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib at 1.2 mg/m2/dose
Number of subjects: 15
Study 15570082 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib at 1.6 mg/m2/dose
Number of subjects: 15
Study 15570082 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 15
Study 10976602 — intervention group
Group type: EXPERIMENTAL
Intervention: Habituation to an actor who talked to the infants
Number of subjects: 0
Study 10976602 — intervention group
Group type: EXPERIMENTAL
Intervention: Habituation to an actor who reached for and swiped at something
Number of subjects: 0
Study 10976602 — intervention group
Group type: COMPARATOR
Intervention: Control condition (infants only saw the person or object stimulus)
Number of subjects: 0
Study 9549633 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg d-sotalol
Number of subjects: 24
Study 9549633 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg d-sotalol
Number of subjects: 24
Study 9549633 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg/kg d-sotalol
Number of subjects: 24
Study 8368471 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g cefamandole administered preoperatively
Number of subjects: 62
Study 8368471 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemofiltration techniques (HF) in group 1
Number of subjects: 62
Study 8368471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell separation techniques (CS) in group 2
Number of subjects: 62
Study 8368471 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 3) with carotid surgery
Number of subjects: 62
Study 8368471 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of group 1 and group 2
Number of subjects: 62
Study 8368471 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of autologous blood
Number of subjects: 62
Study 8368471 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation time of more than 2.5 h during ECC
Number of subjects: 62
Study 8368471 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional administration of 1 g cefamandole before cardiopulmonary bypass
Number of subjects: 62
Study 3085261 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP intranasally (i.n.)
Number of subjects: 10
Study 3085261 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP subcutaneously (s.c.)
Number of subjects: 10
Study 3085261 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP intravenously (i.v.)
Number of subjects: 10
Study 29180524 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline 300 mg
Number of subjects: 26
Study 29180524 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline 450 mg
Number of subjects: 26
Study 29180524 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline 600 mg
Number of subjects: 26
Study 29180524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 26092476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot trial sample size of 75 for extra small effect size (≤0.1)
Number of subjects: 0
Study 26092476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot trial sample size of 25 for small effect size (0.2)
Number of subjects: 0
Study 26092476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot trial sample size of 15 for medium effect size (0.5)
Number of subjects: 0
Study 26092476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot trial sample size of 10 for large effect size (0.8)
Number of subjects: 0
Study 24533664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial target-driven management
Number of subjects: 3057
Study 24533664 — intervention group
Group type: COMPARATOR
Intervention: Routine care of diabetes according to national guidelines
Number of subjects: 3057
Study 24395987 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of emotional support messages
Number of subjects: 237
Study 24395987 — intervention group
Group type: EXPERIMENTAL
Intervention: Reception of emotional support messages
Number of subjects: 237
Study 24395987 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived bonding
Number of subjects: 237
Study 20669674 — intervention group
Group type: EXPERIMENTAL
Intervention: TXLC + aspirin
Number of subjects: 89
Study 20669674 — intervention group
Group type: EXPERIMENTAL
Intervention: TXLC alone
Number of subjects: 89
Study 20669674 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 89
Study 17721640 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional knee rehabilitation program (quadriceps strengthening and TENS)
Number of subjects: 30
Study 17721640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip oriented rehabilitation program (stretching, hip external rotators strengthening and TENS)
Number of subjects: 30
Study 17721640 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of conventional knee and hip oriented rehabilitation programs
Number of subjects: 30
Study 15730802 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group (routine treatment and early rehabilitation for 28 days, followed by community rehabilitation for 6 months or specialized reinforcement training for 2 months)
Number of subjects: 902
Study 15730802 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment and early rehabilitation for 28 days, followed by self-conducted rehabilitation training for 6 months)
Number of subjects: 902
Study 11558795 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CSF hypocretin levels (<100 pg/ml) in 32 of 38 patients (all HLA-positive)
Number of subjects: 72
Study 11558795 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF leptin levels and adjusted BMI
Number of subjects: 72
Study 11558795 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal hypocretin levels in 4 patients (2 HLA-negative)
Number of subjects: 72